ReviewFrontiers in pharmacology2024
Marine-derived polysaccharides: the potential agents against neurodegenerative diseases.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Natural compounds as multitarget agents in Alzheimer's diseases: evidence fromFrontiers in pharmacology · 2026Pooled it
- Signaling Pathways Triggering Therapeutical Potential of Marine-Derived Polysaccharides in Alzheimer's Disease: A Recent Review.Molecular neurobiology · 2026Review
- Marine Bioactive Compounds from Functional Seafoods: Pharmacological Mechanisms and Health Applications.Marine drugs · 2026Review
- Fucoidan and alginate from brown seaweeds: extraction, structural diversity, biocompatibility, biodegradability, and biomedical applications.Frontiers in plant science · 2026Review
- Therapeutic potential of porphyran in mitigating ischemia-reperfusion injury in gerbil hippocampus.Histology and histopathology · 2026Article
- Emerging neuroprotective mechanisms and therapeutic potential of natural polysaccharides in Alzheimer's disease.Frontiers in aging neuroscience · 2026Review
- The role of microglia in neurodegenerative diseases: from the perspective of ferroptosis.Acta pharmacologica Sinica · 2025Review
- Research progress on natural products in regulating the gut microbiota in Parkinson's disease.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases are primarily characterized by the selective loss of neurons in the brain, leading to a significant and widespread global public health burden. Although numerous mechanisms underlying neurodegenerative diseases have been elucidated, effective therapeutic strategies are still being explored. Several drugs have been proposed to halt disease progression; however, they often come with severe side effects. Recently, polysaccharides have garnered considerable attention due to their antioxidant, anti-neuroinflammatory, anticholinesterase, and anti-amyloidogenic properties. The ocean contains a large number of animals, plants, algae and fungal species. Its rich sources and wide availability make the research on marine drugs become a hot topic. Recently, polysaccharides dominated by fucoidan and chitosan have been reported to inhibit the progression of neurodegenerative diseases in a variety of ways. In this review article, we provide a comprehensive summary of reported polysaccharides that intervene in neurodegenerative diseases with the aim of exploring their potential as therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.